RC
BIIB icon

Roundview Capital’s Biogen BIIB Stock Holding History

Roundview Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-839
Closed -$296K – 206
2018
Q3 		$296K Hold
839
– – 0.07% 194
2018
Q2 		$244K Sell
839
-450
-35% -$127K 0.06% 205
2018
Q1 		$353K Sell
1,289
-300
-19% -$93.1K 0.1% 172
2017
Q4 		$506K Buy
1,589
+400
+34% +$128K 0.13% 158
2017
Q3 		$372K Sell
1,189
-112
-9% -$33.2K 0.11% 173
2017
Q2 		$353K Buy
+1,301
New +$344K 0.1% 176

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Roundview Capital's BIIB Position: Q4 2018 in Review

Roundview Capital sold out of Biogen (BIIB) in Q4 2018, closing a stake of 839 shares — an estimated $296K sold.

Roundview Capital first reported a position in BIIB in Q2 2017 and held it in 6 quarters. The position peaked at $506K in Q4 2017. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • Roundview Capital reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • Roundview Capital sold 839 Biogen shares in Q4 2018, an estimated $296K.
  • Roundview Capital first reported a position in Biogen in Q2 2017 and held it in 6 quarters.
  • Roundview Capital's Biogen position peaked at $506K in Q4 2017.
  • 1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Roundview Capital's 13F filing for Q4 2018, filed 13 Feb 2019.